In a patient with a history of untreated chronic myeloid leukemia presenting with hemoptysis, what are the differential diagnoses?

Differential Diagnoses for Hemoptysis in Untreated CML

In a patient with untreated chronic myeloid leukemia presenting with hemoptysis, you must immediately consider disease progression to blast phase with pulmonary leukemic infiltration, leukostasis from extreme hyperleukocytosis, infection (particularly fungal or mycobacterial given immunocompromise), and bleeding diathesis from thrombocytopenia or platelet dysfunction.

CML-Specific Causes (Priority Differentials)

1. Disease Progression with Pulmonary Involvement

• Blast phase CML with extramedullary infiltration: Extramedullary involvement (excluding liver and spleen) including lung is a defining criterion for blast phase 1
• Occurs in approximately 20-30% of blast crisis cases
• Look for: rapidly rising blast count (≥30% by ELN criteria), fever, bone pain, constitutional symptoms 1
• This represents disease transformation and carries grave prognosis without immediate treatment

2. Leukostasis

• Uncommon in chronic phase despite WBC often exceeding 100 × 10⁹/L, but becomes critical concern in untreated disease 1
• Pulmonary leukostasis manifests as dyspnea, hypoxia, and can cause alveolar hemorrhage
• More likely if WBC >200-300 × 10⁹/L 2
• Requires urgent leukapheresis and immediate TKI initiation

3. Thrombocytopenia or Platelet Dysfunction

• Bleeding manifestations occur with low platelet count and/or platelet dysfunction 1
• Check: platelet count, bleeding time, and coagulation studies
• Retinal hemorrhages may coexist, suggesting systemic bleeding tendency 1

4. Thrombotic Complications

• Paradoxically, thrombosis can occur with marked thrombocytosis (>1000 × 10⁹/L) 1
• Pulmonary embolism with infarction can cause hemoptysis
• More common in untreated disease with extreme leukocytosis

Infection-Related Causes (High Priority in Untreated CML)

5. Opportunistic Infections

• Fungal pneumonia (Aspergillus, Mucor): Particularly if any degree of neutropenia or monocytopenia exists
• Mycobacterial infection (TB or atypical mycobacteria): CML patients have impaired cell-mediated immunity
• Bacterial pneumonia with necrotizing features: Including S. aureus, gram-negatives
• Untreated CML creates functional immunodeficiency even without neutropenia 3

6. Post-Obstructive Pneumonia

• If splenomegaly is massive, consider splenic infarction with secondary infection
• Leukemic infiltrates can create endobronchial obstruction

Other Hematologic Complications

7. Diffuse Alveolar Hemorrhage (DAH)

• Rare but life-threatening presentation of acute leukemia, can occur in CML blast crisis 4
• Presents with hemoptysis, dyspnea, diffuse ground-glass opacities on imaging
• Requires bronchoscopy with serial lavage showing progressively bloodier returns

8. Pulmonary Extramedullary Hematopoiesis

• Rare complication of myeloproliferative disorders 5
• Presents with progressive dyspnea, ground-glass opacities
• Can cause hemoptysis through vascular disruption

Standard Hemoptysis Differentials (Must Still Consider)

9. Bronchogenic Carcinoma

• CML patients are not immune to second malignancies
• Particularly relevant if patient has smoking history
• Age-appropriate screening considerations apply

10. Pulmonary Embolism with Infarction

• Hypercoagulable state from untreated CML
• Consider if pleuritic chest pain, sudden onset dyspnea

11. Bronchiectasis/Chronic Bronchitis

• Common causes in general population 6, 7
• May be exacerbated by immunocompromise

Critical Diagnostic Approach

Immediate laboratory evaluation:

• CBC with differential (look for blast percentage, WBC count >100-300 × 10⁹/L)
• Peripheral smear review for blasts, immature cells
• Platelet count and coagulation studies
• Blood cultures if febrile

Imaging:

• Chest X-ray immediately
• CT chest with contrast to evaluate for infiltrates, masses, pulmonary embolism
• Look specifically for ground-glass opacities (DAH, leukemic infiltration) vs. consolidation (infection)

Bone marrow examination urgently if:

• Blast percentage in blood suggests progression (≥15% suggests accelerated phase, ≥30% blast phase by ELN criteria) 1
• Need to distinguish chronic vs. accelerated vs. blast phase

Bronchoscopy indications:

• Suspected DAH (serial lavage)
• Localized lesion on imaging
• Persistent hemoptysis without clear etiology
• To obtain microbiologic samples if infection suspected

Common Pitfalls

• Assuming leukostasis only occurs with extreme WBC: Can occur at lower counts in blast crisis
• Missing blast phase: Untreated CML will progress; extramedullary disease including lung is diagnostic of blast phase 1
• Delaying TKI therapy: Even with active bleeding, addressing the underlying CML is critical
• Overlooking infection: Functional immunodeficiency exists even with high WBC counts 3
• Not checking for T315I or other mutations: If this is actually treated but failing therapy, mutation analysis guides TKI selection 1

The most critical distinction is whether this represents disease progression to blast phase with pulmonary involvement versus infection versus bleeding from cytopenias/platelet dysfunction, as this fundamentally changes management urgency and approach.